MQ enters the week after Q1 results with short sellers adding to positions and the Street largely neutral — a setup that reflects how much uncertainty still surrounds the payments platform's growth trajectory.
The clearest development this week is in the short book. Short interest has climbed steadily since mid-April and now stands near its highest level in six weeks at 4.84% of the free float, up from roughly 4.19% on April 17. That build coincided almost exactly with the Q1 earnings release on May 5, when the stock fell 8.5% in a single session. The trajectory is clear: shorts were already adding ahead of results and continued doing so after them. That said, the lending market is not tight. Availability is extremely loose — utilization is running at just 2.54% against a 52-week high of 7.53%, meaning there is ample capacity in the borrow pool for further short-selling without any squeeze pressure. Cost to borrow has actually eased over the week, falling to 0.44% from around 0.59% a month ago. Shorts are not facing friction.
Options positioning tells a more relaxed story. The put/call ratio at 0.155 is actually fractionally below its 20-day average of 0.162, with a z-score of -1.5 — meaning options traders are leaning call-heavy rather than defensive. That divergence from the short-interest build is notable. Shorts are rebuilding, but the broader options market is not piling into protection. The PCR has been trending lower all week from 0.162 on Monday, reinforcing the call-skewed tilt.
The Street remains in a cautious holding pattern, but there are signs of marginal improvement. UBS lifted its target to $4.75 from $4.25 just days ago on May 6, maintaining Neutral — a modest constructive nudge after a string of cuts. That follows earlier rounds of target reductions: Morgan Stanley trimmed to $5.00 back in February, JP Morgan cut to $6.00 from $8.00 in the same month, and Mizuho downgraded to Neutral in January. The pattern of the past six months has been a slow compression of targets toward current trading levels. Mean analyst target is now $5.19, roughly 24% above the $4.17 close — positive implied upside, though the consensus rating of "buy" rests on just one outperform rating with the majority of coverage sitting at neutral. Factor scores support a nuanced read: EPS momentum is extraordinary, ranking in the 99th percentile on a 30-day basis and 100th percentile over 90 days, with forward EPS growth also ranking in the 92nd percentile. But EPS surprise itself ranks near the bottom at the 4th percentile, a reminder that beating on EPS has not been the issue — guidance and revenue mix have been the sticking points. The short score of 41.1 sits in the lower third of the universe, suggesting the stock does not yet screen as a high-conviction short on aggregate metrics.
The ownership picture has one feature worth flagging. T. Rowe Price remains the dominant institutional holder with 20% of shares, barely changed from last reported. Invesco added 1.6 million shares and Capital Research Management established a fresh 6.1-million-share position as of December. That institutional accumulation at the lower price levels contrasts with the modest insider selling: two directors sold small parcels in mid-to-late April following share award grants, and the CAO trimmed a similarly modest position in April. The net insider position over 90 days is positive at roughly $2.4 million, almost entirely driven by award grants rather than open-market purchases — not a strong directional signal either way.
What to watch next: Q2 results are calendared for June 10, and the gap between the EPS momentum scores (exceptional) and the EPS surprise rank (near zero) makes that print the central question — whether the company can translate improving forward estimates into an actual beat against quarterly consensus, particularly on gross profit given the renegotiated platform partnership impact on revenue accounting.
See the live data behind this article on ORTEX.
Open MQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
